Defining the optimal local treatment approach in stage III non-small cell lung cancer: Surgery versus concurrent chemoradiation after induction chemoimmunotherapy

Melek Yakar

doi:10.36922/ARNM025400052

Advances in Radiotherapy & Nuclear Medicine ›› 2026, Vol. 4 ›› Issue (1) :108 -109. DOI: 10.36922/ARNM025400052

LETTER TO EDITOR

research-article

Defining the optimal local treatment approach in stage III non-small cell lung cancer: Surgery versus concurrent chemoradiation after induction chemoimmunotherapy

Melek Yakar ^*

Author information +

History +

PDF

Cite this article

Download citation ▾

Melek Yakar. Defining the optimal local treatment approach in stage III non-small cell lung cancer: Surgery versus concurrent chemoradiation after induction chemoimmunotherapy. Advances in Radiotherapy & Nuclear Medicine, 2026, 4(1): 108-109 DOI:10.36922/ARNM025400052

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022; 40(12):1301-1311. doi:10.1200/JCO.21.01308.

[2]

Peters S, Tan DS, Gerber DE, et al. CheckMate 73L: Phase III study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab ± ipilimumab versus chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III NSCLC. Immuno Oncol Technol. 2024;24:100808. doi: 10.1016/j.iotech.2024.100808

[3]	Bradley JD, Sugawara S, Lee KH, et al. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. ESMO Open. 2024;9:102986. doi: 10.1016/j.esmoop.2024.102986

[4]	Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023; 389(18):1672-1684. doi: 10.1056/NEJMoa2304875

[5]	Cascone T, Spicer JD, Pulla MP. Perioperative nivolumab in resectable lung cancer. Reply. N Engl J Med. 2024; 391(6):573-574. doi: 10.1056/NEJMc2407267

[6]	Forde PM, Spicer J, Provencio M, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2025; 393(8):741-752. doi: 10.1056/NEJMoa2502931